340B Omnibus Guidance Withdrawn

The 340B omnibus guidance was withdrawn again. The largely accepted reason is the Trump administration's emphasis on less regulation.
read more

Drug Pricing Debate

PBM's and pharmaceutical manufacturers continue to point fingers of blame at each other over the rising cost of drug pricing. This opinion article points to drug rebates as a source of the problem.
read more